RxDoctor Payments Data

Stephanie Hart

Nurse Practitioner · Post Falls, IDNPI 1659692200

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $14,823 of the $17,635 with a category attached, or 84.1%. It is spread thinly across 60 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,635in general payments, 2019–2025

Across 678 payments — averaging $26.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Johnson & Johnson$1K
  • Pfizer$1K
  • Novartis$975
  • Seagen Inc.$843
  • plus $10K from 54 others
$2,500in research payments, 2019–2025

Across 1 payment — averaging $2500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$3K

What the payments were for

  • Speaking & faculty fees$1,5009%
  • Travel & lodging$70%
  • Food & beverage$14,82384%
  • Education$1,3057%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen12$1,884
E.r. Squibb & Sons, L.L.C.57$1,796
Johnson & Johnson48$1,198
Pfizer52$1,013
Novartis74$975
Seagen Inc.16$843
Merck34$792
Bristol Myers Squibb37$629
Regeneron Healthcare Solutions, Inc.24$574
Genentech USA, Inc.30$525
AbbVie16$496
AVEO Pharmaceuticals, Inc.16$486
Astellas Pharma US Inc11$395
Exelixis Inc.24$394
Sanofi11$372
Incyte Corporation10$351
GSK20$337
Boehringer Ingelheim12$321
Lilly USA, LLC14$309
Eisai Inc.14$287
Beigene USA, Inc.9$265
Bayer10$244
Daiichi Sankyo Inc.4$188
Takeda Pharmaceuticals U.S.A., Inc.7$182
Gilead7$154
Galvanize Therapeutics, Inc1$145
Janssen Scientific Affairs, LLC1$140
Adaptive Biotechnologies Corporation7$140
Jazz Pharmaceuticals Inc.6$130
Array Biopharma Inc7$115
Sumitomo Pharma America, Inc.5$109
Ipsen Biopharmaceuticals, Inc6$107
Servier Pharmaceuticals LLC5$104
Myriad Genetic Laboratories, Inc.4$98
Acrotech Biopharma Inc.4$94
Spectrum Pharmaceuticals Inc.3$84
Genmab U.S., Inc.3$76
ADC Therapeutics America, Inc.4$74
Taiho Oncology, Inc.3$72
Puma Biotechnology, Inc.4$71
Pharmacosmos Therapeutics Inc.3$70
Springworks Therapeutics, Inc.3$69
EMD Serono, Inc.3$58
Pharmacyclics LLC, An Abbvie Company2$53
Progenics Pharmaceuticals, Inc.2$53
Stemline Therapeutics Inc.2$52
Blueprint Medicines Corporation2$51
Sun Pharmaceutical Industries Inc.2$51
Immunocore Limited1$49
Rigel Pharmaceuticals, Inc.2$49
Beone Medicines USA, Inc.2$44
Accord Healthcare, Inc.2$42
Sobi, Inc1$39
Mirati Therapeutics, Inc.2$38
AstraZeneca1$34
Dendreon Pharmaceuticals LLC1$30
CTI Biopharma Corp.1$28
Menarini Silicon Biosystems, Inc.1$26
Fennec Pharmaceuticals, Inc.1$24
Azurity Pharmaceuticals, Inc.1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,635 in reported general payments places this provider in the 95th percentile of 570 nurse practitioner providers in Idaho.

See all nurse practitioner providers in Idaho

Medicare billing

Part B allowed, 2024
$48,332
Medicare patients
25
Services billed
2,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$24,813
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen80$1,971
Oxycodone Hcl58$1,093
Diclofenac Sodium15$1,065
Duloxetine Hcl40$892
Hydrocortisone29$844
Prochlorperazine Maleate49$772
Gabapentin61$764
Ondansetron OdtOndansetron24$726
Dexamethasone51$655
Levothyroxine Sodium113$655
Prednisone130$602
Potassium Chloride28$547
Letrozole43$541
Fluconazole28$538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,013$24,81335 claims
Lilly USA, LLCOlanzapine$309$9213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 570 nurse practitioner providers in Idaho.

Other nurse practitioner in Post Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →